 Opiate Substitution Treatment
"Opiate Substitution Treatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Medical treatment for opioid dependence using a substitute opiate such as METHADONE or BUPRENORPHINE.
| Descriptor ID |
D058850
|
| MeSH Number(s) |
E02.319.620
|
| Concept/Terms |
Opiate Substitution Treatment- Opiate Substitution Treatment
- Opiate Substitution Treatments
- Substitution Treatment, Opiate
- Substitution Treatments, Opiate
- Treatment, Opiate Substitution
- Treatments, Opiate Substitution
- Opioid Substitution Treatment
- Opioid Substitution Treatments
- Substitution Treatment, Opioid
- Substitution Treatments, Opioid
- Treatment, Opioid Substitution
- Treatments, Opioid Substitution
- Opioid Substitution Therapy
- Opioid Substitution Therapies
- Substitution Therapies, Opioid
- Substitution Therapy, Opioid
- Therapies, Opioid Substitution
- Therapy, Opioid Substitution
- Opiate Replacement Therapy
- Opiate Replacement Therapies
- Replacement Therapies, Opiate
- Replacement Therapy, Opiate
- Therapies, Opiate Replacement
- Therapy, Opiate Replacement
- Opioid Replacement Therapy
- Opioid Replacement Therapies
- Replacement Therapies, Opioid
- Replacement Therapy, Opioid
- Therapies, Opioid Replacement
- Therapy, Opioid Replacement
|
Below are MeSH descriptors whose meaning is more general than "Opiate Substitution Treatment".
Below are MeSH descriptors whose meaning is more specific than "Opiate Substitution Treatment".
This graph shows the total number of publications written about "Opiate Substitution Treatment" by people in UAMS Profiles by year, and whether "Opiate Substitution Treatment" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 4 | 4 | | 2022 | 1 | 3 | 4 | | 2021 | 0 | 1 | 1 | | 2020 | 5 | 2 | 7 | | 2019 | 4 | 1 | 5 | | 2018 | 2 | 2 | 4 | | 2016 | 2 | 0 | 2 | | 2015 | 2 | 0 | 2 | | 2014 | 3 | 0 | 3 | | 2013 | 4 | 5 | 9 | | 2012 | 0 | 2 | 2 | | 2011 | 1 | 1 | 2 | | 2010 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Opiate Substitution Treatment" by people in Profiles over the past ten years.
-
Fortney JC, Ratzliff AD, Blanchard BE, Johnson M, Ferro L, Austin EJ, Williams EC, Duncan MH, Merrill JO, Thomas J, Kitay B, Schoenbaum M, Heagerty PJ, Saxon AJ. Does Screening for Opioid Use Disorder in Primary Care Increase the Percentage of Patients With a New Diagnosis? Ann Intern Med. 2023 10; 176(10):1431-1433.
-
Tsai PF, Oliveto AH, Landes RD, Mancino MJ. Characteristics of patients undergoing medication-assisted -treatment for opioid use disorder and their interest in Tai Chi practice. J Opioid Manag. 2023 Jul-Aug; 19(4):329-341.
-
Jones CM, Shoff C, Blanco C, Losby JL, Ling SM, Compton WM. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2023 05 01; 80(5):508-514.
-
Thompson RG, Bollinger M, Mancino MJ, Hasin D, Han X, Bush KA, Kilts CD, James GA. Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial. Trials. 2023 Apr 04; 24(1):255.
-
Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2022 10 01; 79(10):981-992.
-
Ali MM, Ghertner R. Is buprenorphine treatment availability associated with decreases in substantiated cases of child maltreatment? J Subst Abuse Treat. 2022 08; 139:108780.
-
Pro G, Hayes C, Brown CC, Goree J, Zaller N. Individual and Health Policy Factors Associated With Positive Heroin and Opioid Treatment Response: United States, 2018. Am J Public Health. 2022 02; 112(S1):S66-S76.
-
Hayes CJ, Cucciare MA, Martin BC, Hudson TJ, Bush K, Lo-Ciganic W, Yu H, Charron E, Gordon AJ. Using data science to improve outcomes for persons with opioid use disorder. Subst Abus. 2022; 43(1):956-963.
-
Lin LA, Fortney JC, Bohnert ASB, Coughlin LN, Zhang L, Piette JD. Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder. J Subst Abuse Treat. 2022 02; 133:108492.
-
Zaller N, Brinkley-Rubinstein L. MOUD Provision in Correctional Settings During Time of COVID-19: Prevention and Solutions. J Addict Med. 2020 12; 14(6):e290-e292.
-
Ray-Griffith S, Tharp E, Coker JL, Catlin D, Knight B, Stowe ZN. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention. Am J Addict. 2021 01; 30(1):43-48.
-
Ghertner R, Ali MM. Increases in Providers With Buprenorphine Waivers in the United States From 2016 to 2019. Psychiatr Serv. 2020 09 01; 71(9):971.
-
Pro G, Utter J, Haberstroh S, Baldwin JA. Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year. Drug Alcohol Depend. 2020 04 01; 209:107952.
-
Pro G, Zaller N. Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in U.S. healthcare settings. PLoS One. 2020; 15(2):e0228755.
-
Pro G, Utter J, Cram J, Baldwin J. Racial/Ethnic and Gender Differences in Associations of Medication-Assisted Therapy and Reduced Opioid Use between Outpatient Treatment Admission and Discharge. J Psychoactive Drugs. 2020 Apr-Jun; 52(2):186-194.
-
Peterson LE, Morgan ZJ, Borders TF. Practice Predictors of Buprenorphine Prescribing by Family Physicians. J Am Board Fam Med. 2020 Jan-Feb; 33(1):118-123.
-
McClellan C, Fingar KR, Ali MM, Olesiuk WJ, Mutter R, Gibson TB. Price elasticity of demand for buprenorphine/naloxone prescriptions. J Subst Abuse Treat. 2019 11; 106:4-11.
-
Bolin EH, Escalona-Vargas D, Daily JA, Siegel ER, Lowery CL, Coker J, Stowe ZN, Eswaran H. Magnetocardiographic identification of prolonged fetal corrected QT interval in women receiving treatment for opioid use disorder. J Obstet Gynaecol Res. 2019 Oct; 45(10):1989-1996.
-
Derefinko KJ, Salgado Garc?a FI, Talley KM, Bursac Z, Johnson KC, Murphy JG, McDevitt-Murphy ME, Andrasik F, Sumrok DD. Adverse childhood experiences predict opioid relapse during treatment among rural adults. Addict Behav. 2019 09; 96:171-174.
-
Gressler LE, Shah S, Shaya FT. Association of Criminal Statutes for Opioid Use Disorder With Prevalence and Treatment Among Pregnant Women With Commercial Insurance in the United States. JAMA Netw Open. 2019 03 01; 2(3):e190338.
-
Wen H, Borders TF, Cummings JR. Trends In Buprenorphine Prescribing By Physician Specialty. Health Aff (Millwood). 2019 01; 38(1):24-28.
-
Coker JL, Catlin D, Ray-Griffith S, Knight B, Stowe ZN. Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence. Drug Alcohol Depend. 2018 11 01; 192:146-149.
-
Gressler LE, Titus-Glover D, Shaya FT. Treatment modalities for pregnant women with opioid use disorder. Lancet. 2018 08 18; 392(10147):551.
-
Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, Seal D. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018 11; 86:104-110.
-
Brinkley-Rubinstein L, McKenzie M, Macmadu A, Larney S, Zaller N, Dauria E, Rich J. A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release. Drug Alcohol Depend. 2018 03 01; 184:57-63.
-
Kumar N, Stowe ZN, Han X, Mancino MJ. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program. Am J Addict. 2016 10; 25(7):542-8.
-
Naeger S, Ali MM, Mutter R, Mark TL, Hughey L. Prescriptions Filled Following an Opioid-Related Hospitalization. Psychiatr Serv. 2016 11 01; 67(11):1262-1264.
-
Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016; 35(1):22-35.
-
Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, Noska A, Reddy M, Zaller N. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015 Jul 25; 386(9991):350-9.
-
Zaller N, Mazhnaya A, Larney S, Islam Z, Shost A, Prokhorova T, Rybak N, Flanigan T. Geographic variability in HIV and injection drug use in Ukraine: implications for integration and expansion of drug treatment and HIV care. Int J Drug Policy. 2015 Jan; 26(1):37-42.
-
Christensen DR, Landes RD, Jackson L, Marsch LA, Mancino MJ, Chopra MP, Bickel WK. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014 Dec; 82(6):964-72.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|